The stock of Lexicon Pharmaceuticals Inc (NASDAQ: LXRX) has increased by 4.02 when compared to last closing price of 1.74.Despite this, the company has seen a gain of 7.74% in its stock price over the last five trading days. globenewswire.com reported 2024-09-27 that Patient randomization is underway in SONATA-HCM clinical trial evaluating Lexicon’s novel dual SGLT1 and SGLT2 inhibitor in this underserved and growing patient population
Is It Worth Investing in Lexicon Pharmaceuticals Inc (NASDAQ: LXRX) Right Now?
Moreover, the 36-month beta value for LXRX is 1.28. Analysts have varying opinions on the stock, with 1 analysts rating it as a “buy,” 3 as “overweight,” 3 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for LXRX is 349.07M and currently, short sellers hold a 7.73% of that float. On October 14, 2024, LXRX’s average trading volume was 2.82M shares.
LXRX’s Market Performance
LXRX’s stock has seen a 7.74% increase for the week, with a 6.47% rise in the past month and a -18.83% fall in the past quarter. The volatility ratio for the week is 4.66%, and the volatility levels for the past 30 days are at 5.22% for Lexicon Pharmaceuticals Inc. The simple moving average for the past 20 days is 10.70% for LXRX’s stock, with a -4.18% simple moving average for the past 200 days.
Analysts’ Opinion of LXRX
Many brokerage firms have already submitted their reports for LXRX stocks, with H.C. Wainwright repeating the rating for LXRX by listing it as a “Buy.” The predicted price for LXRX in the upcoming period, according to H.C. Wainwright is $10 based on the research report published on June 17, 2024 of the current year 2024.
Leerink Partners, on the other hand, stated in their research note that they expect to see LXRX reach a price target of $5. The rating they have provided for LXRX stocks is “Outperform” according to the report published on April 30th, 2024.
Jefferies gave a rating of “Hold” to LXRX, setting the target price at $3 in the report published on March 07th of the previous year.
LXRX Trading at 8.86% from the 50-Day Moving Average
After a stumble in the market that brought LXRX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -51.47% of loss for the given period.
Volatility was left at 5.22%, however, over the last 30 days, the volatility rate increased by 4.66%, as shares surge +10.74% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +6.49% upper at present.
During the last 5 trading sessions, LXRX rose by +7.44%, which changed the moving average for the period of 200-days by +23.63% in comparison to the 20-day moving average, which settled at $1.6348. In addition, Lexicon Pharmaceuticals Inc saw 18.30% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at LXRX starting from COATS LONNEL, who proposed sale 300,000 shares at the price of $1.60 back on Aug 15 ’24. After this action, COATS LONNEL now owns shares of Lexicon Pharmaceuticals Inc, valued at $480,000 using the latest closing price.
COATS LONNEL, the Chief Executive Officer of Lexicon Pharmaceuticals Inc, purchase 90,000 shares at $1.05 during a trade that took place back on Nov 16 ’23, which means that COATS LONNEL is holding 914,359 shares at $94,797 based on the most recent closing price.
Stock Fundamentals for LXRX
Current profitability levels for the company are sitting at:
- -54.12 for the present operating margin
- 0.81 for the gross margin
The net margin for Lexicon Pharmaceuticals Inc stands at -55.09. The total capital return value is set at -0.57. Equity return is now at value -94.10, with -58.14 for asset returns.
Based on Lexicon Pharmaceuticals Inc (LXRX), the company’s capital structure generated 0.3 points at debt to capital in total, while cash flow to debt ratio is standing at -1.94. The debt to equity ratio resting at 0.42. The interest coverage ratio of the stock is -11.96.
Currently, EBITDA for the company is -171.2 million with net debt to EBITDA at -0.36. When we switch over and look at the enterprise to sales, we see a ratio of 198.45. The receivables turnover for the company is 1.39for trailing twelve months and the total asset turnover is 0.01. The liquidity ratio also appears to be rather interesting for investors as it stands at 11.51.
Conclusion
To wrap up, the performance of Lexicon Pharmaceuticals Inc (LXRX) has been better in recent times. The stock has received a mixed of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
